SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
730There will be enough Cabo stuff presented over the weekend and on Monday to maketom pope-6/2/2011
729I don't remember seeing this posted here... hammerstockblog.com CabozantiniIan@SI-6/2/2011
728ASCO 2011: The Advocate Perspective by Howard Soule, PhD in ASCO 2011 Wednesday,IRWIN JAMES FRANKEL-6/1/2011
727YM - supermedx Cabo's prospects in MTC 31-May-11 05:50 pm refresherIRWIN JAMES FRANKEL-5/31/2011
726Expression of MET in Human Tumors by Peter Lamb, PhD in ASCO 2011 Friday, May 27IRWIN JAMES FRANKEL-5/27/2011
725Toward A New Paradigm for Prostate Cancer Therapy by Matthew R. Smith, MD, PhD iIRWIN JAMES FRANKEL-5/25/2011
724exelixis.com Data From a Phase 1 Clinical Trial of Exelixis’ Cabozantinib PubliIRWIN JAMES FRANKEL-5/23/2011
723exelixis.com The Prostate Cancer Treatment Landscape: Then and Now by Karim FizIRWIN JAMES FRANKEL-5/23/2011
722exelixis.com Dual Inhibition of MET and VEGF: Beyond Antiangiogenesis by DonaldIRWIN JAMES FRANKEL-5/21/2011
721exelixis.com Evolution of Targeted Therapies: How We Got Here by Frank McCormicIRWIN JAMES FRANKEL-5/21/2011
720Seems to me that bone MRI's would likely resolve the issue of what is happenBiomaven-5/20/2011
719YM - clarksterh responds to icprecipice <<Why is it not reasonable to conIRWIN JAMES FRANKEL-5/20/2011
718Thanks Ken This from earnie on YM For comparison here is a link to the Nov 18,IRWIN JAMES FRANKEL-5/19/2011
717You were confused by the abbreviations. PR=Partial. SD=Stable. R=Platinum Reskenhott-5/18/2011
716The table I created may be misleading and comparing apples to oranges. The NoveIRWIN JAMES FRANKEL-5/18/2011
715Sheesh! Thanks to pcrutch! Miami by 4, 10 left.scaram(o)uche-5/18/2011
714Ovarian mRecist data looks like it improved over the November data as follows: IRWIN JAMES FRANKEL-5/18/2011
713Swiped this from IH's pcrutch: Lots of ASCO abstract links ARIA ResultsIRWIN JAMES FRANKEL-5/18/2011
712Slight pop on modest volume durin AH trading. Exelixis, Inc. (EXEL) After HoursIan@SI-5/18/2011
711DJN's summary of the highlights... UPDATE: AstraZeneca, Exelixis Cancer DruIan@SI-5/18/2011
710It would seem the market liked the EXEL abstracts, but wasn't impressed by Atom pope-5/18/2011
709Link to abstracts: abstractsearch.asco.orgIRWIN JAMES FRANKEL-5/18/2011
708>>I suspect I'd lean toward the drug with the best results. i.e. - I sIRWIN JAMES FRANKEL-5/18/2011
707Unless there's a major quality of life AE disadvantage to Cabo, I suspect I&Ian@SI-5/18/2011
706ONJ of the jaw could be a problem for Amgen. Anyway, I don't think XL-184&rkrw-5/18/2011
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News